Hormonal therapies such as progestins have only modest activity in the treatment of advanced endometrial cancer. Mechanisms of resistance to progestin therapy are not well understood. However, activation of the PI3K/AKT/mTOR pathway has been associated with resistance to hormonal therapy and alterations in components of the PI3K/AKT/mTOR pathway, including inactivating mutations in PTEN, activating mutations in PIK3CA, and mutations in PIK3R1, are very common in endometrial carcinomas. mTOR inhibitors, including temsirolimus, everolimus, and ridaforolimus, are also known to be active against endometrial cancer, and interest has been stimulated in combinations of hormonal treatment with mTOR inhibitors, as both therapies have single-agent activity, and it is hypothesized that mTOR inhibition would enhance sensitivity to hormonal therapy.
Median survival for women with recurrent or metastatic disease is only 12 to 15 months. The most commonly used systemic treatment for advanced disease at this time is platinum/taxane-based chemotherapy, which has produced higher response rates and longer median progression-free survivals than hormonal therapy, but progestins remain useful, and occasionally produce prolonged disease control. Mammalian target of rapamycin (mTOR) inhibitors have also recently been shown to have modest single-agent activity.
Type I and Type II Endometrial Carcinoma
Endometrial cancers are often divided into two conceptual categories: type I and type II. 2 About 80 % of endometrial carcinomas are type I, i.e.
of endometrioid histology with low or intermediate grade. These cancers can arise in the setting of persistent unopposed estrogen stimulation, and tend to occur in perimenopausal women. 3 They are generally preceded by endometrial hyperplasia and are usually estrogen-and progesteronereceptor (ER/PR) positive. Molecular alterations associated with type I tumors include deletions/inactivating mutations of the PTEN tumor suppressor gene (36-83 %) , microsatellite instability (20-40 %), mutations of K-ras (15-30 %) , and gain of function mutations in β-catenin (25-40 %). [4] [5] [6] By contrast, type II tumors are histologically nonendometrioid e.g. serous or clear cell, and have no association with excess endogenous or exogenous estrogen. They tend to occur in older women, and are aggressive with a proclivity for lymphovascular invasion, distant spread, and deep tissue invasion; they account for nearly half of endometrial cancer deaths. 7 The genetic alterations associated with type II tumors include aneuploidy, p53
mutations (80-90 %), p16 inactivation (40 %), overexpression of human epidermal growth factor receptor 2 (HER-2)/neu (40-80 %), and E-cadherin alterations (80-90 %). [4] [5] [6] Mutations in PIK3CA (gene encoding the catalytic subunit of PI3K) and PIK3R (which encodes the regulatory subunit of PI3K)
can occur in both subtypes, although they appear to be more common in type I cancers. 8, 9 Increased signaling of the PI3K/AKT/mTOR pathway is associated with a poor prognosis in both type I and type II carcinomas.
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Hormone Therapy in the Treatment of Advanced Endometrial Cancer (see Table 1 )
Since the early studies by Kelly and Baker in 1965, progestin-based therapy has played a role in the treatment of advanced endometrial carcinoma. 11, 12 Trials in chemotherapy-naïve advanced endometrial carcinoma patients have demonstrated response rates of 18-34 % to progestins with median overall survivals of 6-14 months. 13 Commonly used regimens in the US include megestrol acetate (MA) 160 mg/day, or MA for 3 weeks alternating with tamoxifen (TAM) for 3 weeks. The addition of TAM was hypothesized to increase the percentage of endometrial cells that contain PRs, as well as the concentration of surface receptors. 14 While this alternating regimen has not been compared with single-agent megestrol therapy in a randomized trial, the 27 % response rate reported is as high as or higher than that reported with any other hormonal regimen, and TAM causes less weight gain than MA. Dose escalations of MA to 1,000 mg/day did not improve overall survival or progression-free survival. 15 In general, the highest response rates are found in patients with well-differentiated hormone receptor positive tumors. 11 However, objective response rates 
mTOR Inhibitor Therapy in Endometrial Cancer
The mTOR is a protein downstream of PI3 Kinase that is activated by Toxicities were typical of those seen with mTOR-inhibitor therapy, and included fatigue, rash, nausea, diarrhea, mucositis, and pneumonitis.
Asymptomatic pneumonitis was particularly common in this study (42 %) with five patients (8 %) having grade 3 pneumonitis. Low levels of activity were also seen in phase II trials of ridaforolimus and everolimus in women with pretreated disease (see Table 2 ).
More recently, a randomized phase II trial compared ridaforolimus with progestin-based therapy and standard chemotherapy in 130 women with advanced disease who had received one or two prior chemotherapy regimens. Almost one-third of patients had tumors of serous histology, and more than 50 % had grade 3 tumors. Ridaforolimus met the primary endpoint of the study by demonstrating a progression-free survival of 3.6 versus 1.9 months with progestins. 24 Toxicities with ridaforolimus included hyperglycemia, fatigue, diarrhea, anemia, and mucositis, but no grade 3 pneumonitis. 25 Given the toxicities with mTOR-inhibitor therapy, a biologic indicator of which patients are most likely to benefit, but no good predictive marker has emerged to date.
Rationale for Combination of mTOR Inhibitors with Hormone Therapy
The PI3K/AKT/mTOR signaling cascade has been widely implicated in resistance to chemotherapy agents, molecularly targeted agents, such as trastuzumab or gefitinib, radiotherapy, and hormonal therapy. a superior progression-free survival of 10.6 months versus 4.1 months with exemestane alone. 30 The most common grade 3 or 4 adverse events with the combination were stomatitis, anemia, dyspnea, hyperglycemia, fatigue, and pneumonitis (3 %).
Specifically in endometrial cancer, there are in vitro data that mTOR inhibitors increase progesterone messenger RNA (mRNA) expression.
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In addition, in vitro and in vivo xenograft mouse models suggest that MPA activates the PI3K/AKT pathway in progestin-resistant cells, and that inhibiting this pathway reverses progestin resistance in these cell lines. 32 Two phase II trials combining mTOR inhibitors with hormonal therapy have been completed in endometrial cancer, and both have been reported in abstract form (see Table 2 ). The Gynecologic Oncology 
Other Potential Combinations with mTOR Inhibitors in Endometrial Carcinoma
As described above, activation of the PI3K/AKT/mTOR pathway has been implicated as a mechanism of resistance to both trastuzumab and standard cytotoxic chemotherapy, and combining trastuzumab or chemotherapeutic agents with inhibitors of the pathway has overcome resistance in numerous reports. 36 However, given the preclinical data suggesting that PI3K/AKT pathway activation is associated with resistance to trastuzumab, and the encouraging clinical results of the everolimus/trastuzumab combination in breast cancer (described above), trials testing a similar combination in endometrial cancer are of interest. n
